跳转至内容
Merck
CN

601799

氩-40Ar

99.95 atom %

登录 查看组织和合同定价。

关于此项目

线性分子式:
40Ar
化学文摘社编号:
分子量:
39.96
UNSPSC Code:
12142004
PubChem Substance ID:
MDL number:
Isotopic purity:
99.95 atom %
Assay:
≥99.5% (Total Argon), <0.5% (Total others)
Mass shift:
depleted
Form:
gas


isotopic purity

99.95 atom %

assay

≥99.5% (Total Argon), <0.5% (Total others)

form

gas

impurities

<0.5% Total others

mass shift

depleted

SMILES string

[40Ar]

InChI

1S/Ar/i1+0

InChI key

XKRFYHLGVUSROY-IGMARMGPSA-N

Packaging

All gas volumes are quoted at Standard Temperature and Pressure (STP) and not at Normal Temperature and Pressure (NTP). One STP Liter is 7.7% more gas than one NTP Liter.
This product may be available from bulk stock and can be packaged on demand. For information on pricing, availability and packaging, please contact Stable Isotopes Customer Service.


pictograms

Gas cylinder

signalword

Warning

hcodes

Hazard Classifications

Press. Gas Compr. Gas

存储类别

2A - Gases

wgk

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Andrew Riddell et al.
Methods (San Diego, Calif.), 82, 64-73 (2015-03-10)
Sorting performance can be evaluated with regard to Purity, Yield and/or Recovery of the sorted fraction. Purity is a check on the quality of the sample and the sort decisions made by the instrument. Recovery and Yield definitions vary with
Linlin Li et al.
Small (Weinheim an der Bergstrasse, Germany), 11(20), 2429-2436 (2015-01-22)
Herein, the controlled synthesis of 3D hierarchical films on carbon cloth (CC) in a high yield through a hydrothermal process and their high photocatalytic properties are reported. As representative examples, the obtained ZnIn2 S4 /CdIn2 S4 composites are composed of
Kali Janes et al.
Brain, behavior, and immunity, 44, 91-99 (2014-09-16)
Many commonly used chemotherapeutics including oxaliplatin are associated with the development of a painful chemotherapy-induced peripheral neuropathy (CIPN). This dose-limiting complication can appear long after the completion of therapy causing a significant reduction in quality-of-life and impeding cancer treatment. We